Full Fed. Circ. Won't Revisit 'Alarming' Relistor Ruling
The full Federal Circuit has refused to revisit Valeant Pharmaceuticals' loss against Mylan Pharmaceuticals in its patent dispute over the opioid-induced constipation drug Relistor, unmoved by Valeant's argument that the earlier...To view the full article, register now.
Already a subscriber? Click here to view full article